Akero Therapeutics reports Q2 EPS ($2.21), may not compare to consensus (36c)
"The second quarter of 2019 was a period of significant growth for Akero marked by the successful completion of our IPO and the initiation of the BALANCED study, our Phase 2a study evaluating our lead candidate AKR-001 for the treatment of NASH," said Andrew Cheng, M.D., Ph.D., President and CEO of Akero. "Our strong cash position provides us with sufficient resources to complete our Phase 2 clinical program. We remain on track to report results of the BALANCED study's primary endpoint in the first quarter of 2020 and full study results in the second quarter of 2020. The progress we've made this year has provided a strong foundation for the continued development of AKR-001, which has the potential to become a cornerstone of NASH treatment that addresses the underlying metabolic drivers of the disease to reduce liver inflammation and fibrosis, while also improving cardiovascular risk factors." Akero's cash and cash equivalents at June 30 were $162.7M.